Evidence map›Paper›PMID 41647606›Full record

ArticleFrontiers in bioengineering and biotechnology2025

Modeling and validating of oxygen transport in wave bioreactors: optimized experimental mass transfer method and novel Lattice-Boltzmann CFD approach.

S Piontek, J Fitschen, C Weiland, T Habicher, M Schlüter, T Wucherpfennig

Abstract read
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

S PiontekBoehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany.
J FitschenBoehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany.
C WeilandHamburg University of Technology, Hamburg, Germany.
T HabicherBoehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany.
M SchlüterHamburg University of Technology, Hamburg, Germany.
T WucherpfennigBoehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Wave bioreactors are commonly used in biopharmaceutical upstream processes as an intermediate stage between shake flasks and stirred tanks within the seed train. They offer a controlled environment for cell cultivation while minimizing shear stress. Accurate characterization of these systems is essential for optimizing cell culture performance, particularly as state of the art cell lines require higher volumetric mass transfer coefficients

Indexed as

CFDprocess optimizationrocked bioreactorsingle usevolumetric mass transfer coefficientwave bioreactor

Identifiers

PMID41647606
PMCPMC12868168

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.